Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q6EEV6
UPID:
SUMO4_HUMAN
Alternative names:
Small ubiquitin-like protein 4
Alternative UPACC:
Q6EEV6; A1L3W5
Background:
Small ubiquitin-related modifier 4 (SUMO4), a ubiquitin-like protein, plays a crucial role in post-translational modification. It attaches to target lysines on substrates, influencing their localization, stability, or activity. Notably, SUMO4's involvement extends to oxidative stress response, where it conjugates to anti-oxidant enzymes and stress defense proteins, modulating transcriptional activities of various genes including NFKBIA and NR3C1.
Therapeutic significance:
SUMO4's association with Type 1 diabetes mellitus 5 highlights its potential in disease modulation. Understanding the role of Small ubiquitin-related modifier 4 could open doors to potential therapeutic strategies, especially considering its impact on gene transcription and stress response mechanisms.